|
|
 |
 |
|
 |
 |
| In the next year, U.S. regulators may approve gene therapies – to treat sickle cell disease. But gene therapies come with a high price tag — and it’s estimated that roughly 40% of sickle cell patients are covered by #Medicaid. buff.ly/35UOqlP |
|
| 3/14/22, 5:25 PM |
|
|
|
Published by Joseph Thornton MD
Teacher, Clinical Supervisor, [AIdvisor]
Retired Clinical Associate Professor, Psychiatry, University of Florida
Affiliation is for identification only. All content and opinions are my own.
View more posts
Gator Psychiatry 